<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01914081</url>
  </required_header>
  <id_info>
    <org_study_id>CTA/2012/0002</org_study_id>
    <secondary_id>RRC/2011/1169</secondary_id>
    <nct_id>NCT01914081</nct_id>
  </id_info>
  <brief_title>Resveratrol: A Potential Anti- Remodeling Agent in Heart Failure, From Bench to Bedside</brief_title>
  <acronym>RES-HF</acronym>
  <official_title>Resveratrol: A Potential Anti- Remodeling Agent in Heart Failure, From Bench to Bedside (RES-HF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Boniface General Hospital Research Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Centre for Agri-Food Research in Health and Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Agriculture and Agri-Food Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Manitoba Medical Service Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Boniface General Hospital Research Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if resveratrol can improve heart function and
      quality of life. Although, population studies have revealed that a mild to moderate intake of
      red wine reduces cardiovascular disease risk in humans, clinical studies that evaluate the
      potential heart benefits of resveratrol in patients with non-ischemic cardiomyopathy have not
      been previously reported. Accordingly, this research is being done because it will fill this
      deficiency in the information available in the literature and establish the clinical benefits
      of resveratrol in patients with this type of heart disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will conduct a randomized double blinded placebo controlled study of 40
      adults (≥18 to 90 years old). Twenty (20) subjects will be included in the placebo arm, and
      20 in the treatment arm. Patients will be randomly allocated to receive placebo or
      resveratrol. After randomization, the two groups of subjects will be followed up in exactly
      the same way, and the only differences between the care they receive will be those intrinsic
      to the treatment being compared. The randomization will minimize allocation bias, balancing
      both known and unknown prognostic factors, in the assignment of treatments.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 9, 2018</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>Measured by Minnesota living with heart failure score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiac Function</measure>
    <time_frame>12 months</time_frame>
    <description>Echocardiography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxidative Stress</measure>
    <time_frame>12 Months</time_frame>
    <description>Measurement of oxidative stress using the Oxiselect TBARS Assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Antioxidant Status</measure>
    <time_frame>12 Months</time_frame>
    <description>Measurement of total antioxidant status (TAS) level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Marker Measurements</measure>
    <time_frame>12 Months</time_frame>
    <description>Inflammatory markers will be measured by plasma levels of interleukin 6 (IL6) and tumor necrosis factor (TNF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nitric Oxide Determination</measure>
    <time_frame>12 Months</time_frame>
    <description>Total nitric oxide levels will be measured.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Dilated Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Resveratrol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>500 mg (1 capsule BID) of resveratrol for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>500 mg (1 capsule BID) of placebo for 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Resveratrol</intervention_name>
    <description>Patients will receive one uncoated immediate-release caplets containing 500 mg resveratrol, twice daily for the 12 month intervention period</description>
    <arm_group_label>Resveratrol</arm_group_label>
    <other_name>Transmax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients will receive one uncoated caplet containing placebo, twice daily for the 12 month intervention period</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects (between 18-90 years of age) with cardiomyopathy, Heart Failure with reduced
             ejection fraction (HFrEF defined as Left Ventricular Ejection Fraction (LVEF) ≤40%,
             based on most recent assessment)

          -  New York Heart Association (NYHA) Functional class II-III (mild-moderate heart failure
             symptoms)

          -  On optimal medical management for 6 months as per standard care

        Exclusion Criteria:

          -  Severe valvular cardiomyopathy

          -  No surgical intervention planned or in past 6 months

          -  Subjects on \diltiazem (or any other calcium channel blocker)

          -  Patients with a history of serious hypoglycemia requiring hospitalization or
             hyperglycemic emergencies requiring hospitalization in the past 6 months

          -  Subjects on anticoagulants, Coumadin, dabigatran

          -  Subjects on HIV protease inhibitor (saquinivir), immunosupressants (cyclosporine,
             tacrolimus)

          -  Subjects on terfenadine, midazolam, and triazolam

          -  Subjects on sildenafil or any other drugs used to treat erectile dysfunction

          -  • Chronic renal failure (defined as estimated glomerular filtration rate (eGFR) ≤30
             mL/min per 1.73m2)

          -  Known liver cirrhosis

          -  • Other significant comorbidity e.g. cancer affecting ability to complete study

          -  Pregnant or lactating women

          -  Subjects on hormone replacement therapy

          -  Subjects on estrogen containing birth control
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shelley Zieroth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Boniface General Hospital Research Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wendy Janz, RN</last_name>
    <phone>204-237-2793</phone>
    <email>wjanz@exchange.mb.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Boniface General Hospital</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2H 2A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Janz, RN</last_name>
      <phone>204-237-2793</phone>
      <email>wjanz@hsc.mb.ca</email>
    </contact>
    <investigator>
      <last_name>Amrit Malik, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shelley Zieroth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Netticadan, Ph. D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>July 3, 2013</study_first_submitted>
  <study_first_submitted_qc>July 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2013</study_first_posted>
  <last_update_submitted>November 9, 2018</last_update_submitted>
  <last_update_submitted_qc>November 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Boniface General Hospital Research Centre</investigator_affiliation>
    <investigator_full_name>Dr. Amrit Malik</investigator_full_name>
    <investigator_title>Cardiologist</investigator_title>
  </responsible_party>
  <keyword>dilated cardiomyopathy</keyword>
  <keyword>Resveratrol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Resveratrol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

